<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02537951</url>
  </required_header>
  <id_info>
    <org_study_id>NL49568.078.14</org_study_id>
    <nct_id>NCT02537951</nct_id>
  </id_info>
  <brief_title>Autofluorescent Flavoprotein Imaging of Intraepidermal Nerve Fibers: a Pilot Study</brief_title>
  <official_title>Autofluorescent Flavoprotein Imaging of Intraepidermal Nerve Fibers: a Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Erasmus Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Erasmus Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Small fiber neuropathy (SFN) is a common disorder, which has a profound negative impact on
      quality of life because of severe neuropathic pain. To reliably establish a diagnosis of SFN
      is challenging, since neurological examination and nerve conduction studies are often normal.
      Autofluorescent flavoprotein imaging (AFI) is an optical method through which neuronal
      activity in the termination area of small nerve fibers in the spinal cord can be quantified.
      Since the epidermis also contains a high density of small nerve terminals and since the
      number of intraepidermal nerve fibers is greatly reduced in patients with SFN, our hypothesis
      is that AFI intensity is reduced in patients with SFN. To support this hypothesis, a pilot
      study is required in which the investigators first need to confirm the precision of AFI in
      the epidermis of the third finger of 10 healthy volunteers. Secondly, lidocaine/prilocaine
      cream will be used as a negative control. Finally, the AFI signal will be measured after
      application of a 8% capsaicin patch, through which (temporarily) a selective reduction of
      small nerve fibers can be induced, mimicking SFN. Using this experimental design, the
      investigators will be able to test the reliability and validity of AFI for capsaicin-induced
      small nerve fiber degeneration. This would be a significant step in developing an objective,
      rapid and non-invasive diagnostic tool to diagnose patients with SFN, which may also be
      utilized as a biomarker in studies that assess the efficacy of novel treatments for SFN.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The first aim of the current project is to test the precision of AFI in the epidermis of 10
      healthy volunteers. For this purpose, a range of nociceptive electrical stimuli with
      increasing intensities (5Hz @ 0.5mA-1.0mA) and one innocuous control stimulus (2000Hz @1mA)
      will be delivered to the third finger of each subject. The outcome measure is AFI-intensity,
      which is the change in autofluorescence intensity compared to baseline (delta F/F). The
      standard deviation of AFI intensity will be the measure of precision. Pearson's correlation
      coefficient will be calculated between electrical stimulus intensities and AFI intensity. A
      linear correlation needs to be confirmed, since this is a general characteristic of AFI. A
      paired t-tests will be performed to compare AFI intensities following 5Hz @ 1mA stimulation
      and 2000Hz @ 1mA stimulation. Lidocaine/prilocaine cream will be applied to the fingertips of
      the subjects and the electrical stimuli will be repeated, to serve as a negative control
      experiment. A repeated-measures ANOVA will be performed to compare AFI intensities before and
      after application of lidocaine/prilocaine cream.

      The second aim of our study is to validate AFI in experimentally induced small nerve fiber
      degeneration of the epidermis, by comparing AFI intensities in subjects before and one week
      after application of a 8% capsaicin patch to the third fingertip. A repeated-measures ANOVA
      will be performed to compare AFI intensities before and after capsaicin-induced small nerve
      fiber degeneration. Assuming that all subjects develop epidermal small fiber degeneration
      following the 8% capsaicin patch, a statistically significant difference in AFI intensity
      would serve as a proof-of-principle and would provide validity to autofluorescent
      flavoprotein imaging of epidermal nociceptor activity as a diagnostic test for SFN. Comparing
      the distributions of before and after capsaicin-induced small nerve fiber degeneration will
      lead to a probability estimation of having SFN based on the outcome measure, i.e. AFI
      intensity. In future research, false-positive and false-negative consequences will be
      evaluated, leading to cut-off values in patients suspected for SFN.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2015</start_date>
  <completion_date type="Actual">September 2016</completion_date>
  <primary_completion_date type="Actual">July 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>subjects are first undergoing measurements of AFI intensities following increasing nociceptive stimulus intensities, consequently it is tested whether the AFI activity can be blocked by lidocaine/prilocaine and a 8% capsaicin patch, i.e. whether the AFI activity is specific for nociceptor-acitivity</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AFI-intensity After Nociceptive Stimulation</measure>
    <time_frame>Day 1, T=0h (AFI measurements), Day 1, T=6h (AFI measurements after lidocaine/prilocaine), Day 7 (AFI measurements after capsaicin)</time_frame>
    <description>AFI-intensity (delta F/F) at the 3rd fingertip, directly after application of grading nociceptive stimuli</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Small Fiber Neuropathy</condition>
  <arm_group>
    <arm_group_label>AFI intensity in healthy volunteers</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 healthy volunteers, on whose 3rd fingertips AFI intensity is measured through an AFI microscope</description>
  </arm_group>
  <arm_group>
    <arm_group_label>negative control 1: lidocaine/prilocaine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>10 healthy volunteers, on whose 3rd fingertips AFI intensity is measured through an AFI microscope, 1hour after application of lidocaine/prilocaine creme (negative control 1)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>negative control 2: 8% capsaicin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>-10 healthy volunteers, on whose 3rd fingertips AFI intensity is measured through an AFI microscope, 1week after application of an 8% capsaicin patch (negative control 2)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>AFI microscope</intervention_name>
    <description>measurement of AFI intensities following increasing nociceptive stimulus intensities</description>
    <arm_group_label>AFI intensity in healthy volunteers</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>negative control 1: lidocaine/prilocaine</intervention_name>
    <description>measurement of AFI intensities following lidocaine/prilocaine cream</description>
    <arm_group_label>negative control 1: lidocaine/prilocaine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>negative control 2: 8% capsaicin</intervention_name>
    <description>measurement of AFI intensities following 8% capsaicin patch</description>
    <arm_group_label>negative control 2: 8% capsaicin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  healthy volunteers

        Exclusion Criteria:

          -  younger than 18 years

          -  pre-existing neuropathy

          -  previous allergic reaction to local anaesthetics
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joost LM Jongen, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Erasmus MC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dept. Neurology, Erasmus MC</name>
      <address>
        <city>Rotterdam</city>
        <zip>3015 CE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>August 22, 2015</study_first_submitted>
  <study_first_submitted_qc>September 1, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 2, 2015</study_first_posted>
  <results_first_submitted>January 30, 2018</results_first_submitted>
  <results_first_submitted_qc>February 18, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">June 3, 2019</results_first_posted>
  <last_update_submitted>June 1, 2019</last_update_submitted>
  <last_update_submitted_qc>June 1, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Erasmus Medical Center</investigator_affiliation>
    <investigator_full_name>Joost LM Jongen</investigator_full_name>
    <investigator_title>Dr. J.L.M. Jongen, neurologist</investigator_title>
  </responsible_party>
  <keyword>autofluorescent flavoprotein imaging, capsaicin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Small Fiber Neuropathy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lidocaine</mesh_term>
    <mesh_term>Prilocaine</mesh_term>
    <mesh_term>Lidocaine, Prilocaine Drug Combination</mesh_term>
    <mesh_term>Capsaicin</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>June 23, 2014</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/51/NCT02537951/Prot_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>all 10 healthy volunteers underwent 3 experiments, all 10 have completed these experiments:
AFI intensity measurements
lidocaine/prilocaine creme, one hour later followed by AFI intensity measurements
capsaicin patch (2 hours after lidocaine/prilocaine creme), one week later followed by AFI intensity measurements</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>10 Healthy Volunteers</title>
          <description>10 healthy volunteers underwent three procedures, always in the same order:
baseline AFI measurements
application of lidocaine/prilocaine creme, 1 hour later followed by AFI measurements
application of capsaicin patches, 1 week later followed by AFI measurements</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>AFI Intensity in Healthy Volunteers</title>
          <description>10 healthy volunteers, on whose 3rd fingertips AFI intensity is measured through an AFI microscope
AFI microscope: measurement of AFI intensities following increasing nociceptive stimulus intensities
After AFI intensity measurements, the same experiment will be repeated one hour after application of lidocaine/prilocaine creme
After the negative control experiment using lidocaine/prilocaine creme, AFI intensity measurements will be repeated one week after application of a capsaicin 8% patch (second negative control experiment)</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25" lower_limit="20" upper_limit="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Netherlands</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>AFI-intensity After Nociceptive Stimulation</title>
        <description>AFI-intensity (delta F/F) at the 3rd fingertip, directly after application of grading nociceptive stimuli</description>
        <time_frame>Day 1, T=0h (AFI measurements), Day 1, T=6h (AFI measurements after lidocaine/prilocaine), Day 7 (AFI measurements after capsaicin)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AFI Intensity in Healthy Volunteers</title>
            <description>10 healthy volunteers, on whose 3rd fingertips AFI intensity is measured through an AFI microscope
AFI microscope: measurement of AFI intensities following increasing nociceptive stimulus intensities</description>
          </group>
          <group group_id="O2">
            <title>Negative Control 1: Lidocaine/Prilocaine</title>
            <description>10 healthy volunteers, on whose 3rd fingertips AFI intensity is measured through an AFI microscope, 1hour after application of lidocaine/prilocaine creme (negative control 1)
negative control 1: lidocaine/prilocaine: measurement of AFI intensities following lidocaine/prilocaine cream</description>
          </group>
          <group group_id="O3">
            <title>Negative Control 2: 8% Capsaicin</title>
            <description>-10 healthy volunteers, on whose 3rd fingertips AFI intensity is measured through an AFI microscope, 1week after application of an 8% capsaicin patch (negative control 2)
negative control 2: 8% capsaicin: measurement of AFI intensities following 8% capsaicin patch</description>
          </group>
        </group_list>
        <measure>
          <title>AFI-intensity After Nociceptive Stimulation</title>
          <description>AFI-intensity (delta F/F) at the 3rd fingertip, directly after application of grading nociceptive stimuli</description>
          <units>unitless</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.60" spread="0.25"/>
                    <measurement group_id="O2" value="0.25" spread="0.25"/>
                    <measurement group_id="O3" value="0.50" spread="0.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 month</time_frame>
      <group_list>
        <group group_id="E1">
          <title>AFI Intensity in Healthy Volunteers</title>
          <description>10 healthy volunteers-AFI intensity measurements</description>
        </group>
        <group group_id="E2">
          <title>Negative Control 1: Lidocaine/Prilocaine</title>
          <description>10 healthy volunteers-lidocaine/prilocaine creme, one hour lat</description>
        </group>
        <group group_id="E3">
          <title>Negative Control 2: 8% Capsaicin</title>
          <description>10 healthy volunteers-capsaicin patch (2 hours after lidocaine</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Joost L.M. Jongen</name_or_title>
      <organization>Erasmus MC</organization>
      <phone>+31107041415</phone>
      <email>j.jongen@erasmusmc.nl</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

